WO2012170827A3 - Pyrazolopyrimidines et hétérocycles associés comme inhibiteurs de ck2 - Google Patents

Pyrazolopyrimidines et hétérocycles associés comme inhibiteurs de ck2 Download PDF

Info

Publication number
WO2012170827A3
WO2012170827A3 PCT/US2012/041567 US2012041567W WO2012170827A3 WO 2012170827 A3 WO2012170827 A3 WO 2012170827A3 US 2012041567 W US2012041567 W US 2012041567W WO 2012170827 A3 WO2012170827 A3 WO 2012170827A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
pyrazolopyrimidines
inhibitors
activity
related heterocycles
Prior art date
Application number
PCT/US2012/041567
Other languages
English (en)
Other versions
WO2012170827A2 (fr
Inventor
Mustapha Haddach
Joe A. Tran
Fabrice Pierre
Collin F. Regan
Nicholas B. Raffaele
Suchitra Ravula
David M. Ryckman
Original Assignee
Senhwa Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senhwa Biosciences, Inc. filed Critical Senhwa Biosciences, Inc.
Publication of WO2012170827A2 publication Critical patent/WO2012170827A2/fr
Publication of WO2012170827A3 publication Critical patent/WO2012170827A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

L'invention concerne des composés qui inhibent l'activité de la protéine kinase CK2 (activité de CK2) et des compositions contenant de tels composés. Ces composés et compositions sont utiles pour le traitement de troubles prolifératifs tels que le cancer ainsi que d'autres états associés à la kinase incluant l'inflammation, la douleur et certains troubles immunologiques, et présentent la formule générale suivante :
PCT/US2012/041567 2011-06-08 2012-06-08 Pyrazolopyrimidines et hétérocycles associés comme inhibiteurs de ck2 WO2012170827A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161494660P 2011-06-08 2011-06-08
US61/494,660 2011-06-08

Publications (2)

Publication Number Publication Date
WO2012170827A2 WO2012170827A2 (fr) 2012-12-13
WO2012170827A3 true WO2012170827A3 (fr) 2014-05-01

Family

ID=47296763

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/041567 WO2012170827A2 (fr) 2011-06-08 2012-06-08 Pyrazolopyrimidines et hétérocycles associés comme inhibiteurs de ck2

Country Status (1)

Country Link
WO (1) WO2012170827A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845754B2 (en) 2018-10-30 2023-12-19 Kronos Bio, Inc. Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110574A1 (fr) 2013-01-14 2014-07-17 Incyte Corporation Composés de carboxamide aromatique bicyclique utiles comme inhibiteurs de pim kinase
SG10201705662WA (en) 2013-01-15 2017-08-30 Incyte Corp Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
PE20160532A1 (es) 2013-08-23 2016-05-21 Incyte Corp Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim
EP3142652B1 (fr) 2014-05-14 2021-08-25 The Regents of the University of Colorado, a body corporate Acides hydroxamiques hétérocycliques comme inhibiteurs de protéine désacétylase et inhibiteurs doubles de protéine kinase-protéine désacétylase, et leurs procédés d'utilisation
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (fr) 2014-07-14 2016-01-21 Incyte Corporation Composés carboxamide hétéroaromatiques bicycliques utiles en tant qu'inhibiteurs de kinases pim
EP3778605A3 (fr) * 2015-02-13 2021-03-10 Dana Farber Cancer Institute, Inc. Inhibiteurs de lrrk2 et leurs méthodes de production et d'utilisation
WO2016196244A1 (fr) 2015-05-29 2016-12-08 Incyte Corporation Composés de pyridineamine utiles en tant qu'inhibiteurs de kinase pim
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
WO2017070137A1 (fr) * 2015-10-20 2017-04-27 Bristol-Myers Squibb Company Combinaison d'inhibiteurs de ck2 et de modulateurs de points de contrôle immunitaires pour le traitement du cancer
CA3028727A1 (fr) * 2016-06-24 2017-12-28 Polaris Pharmaceuticals, Inc. Inhibiteurs de ck2, leurs compositions et methodes associees
CN113444046B (zh) * 2016-07-20 2023-10-27 纳莹(上海)生物科技有限公司 一种荧光探针及其制备方法和用途
JP7216705B2 (ja) 2017-07-28 2023-02-02 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用方法
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010135581A1 (fr) * 2009-05-20 2010-11-25 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines et hétérocycles associés en tant qu'inhibiteurs de kinases
WO2011031979A1 (fr) * 2009-09-11 2011-03-17 Cylene Pharmaceuticals Inc. Lactames substitués par hétérocycle pharmaceutiquement utiles
WO2011068667A1 (fr) * 2009-12-04 2011-06-09 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines et hétérocycles associés en tant qu'inhibiteurs de ck2

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010135581A1 (fr) * 2009-05-20 2010-11-25 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines et hétérocycles associés en tant qu'inhibiteurs de kinases
WO2011031979A1 (fr) * 2009-09-11 2011-03-17 Cylene Pharmaceuticals Inc. Lactames substitués par hétérocycle pharmaceutiquement utiles
WO2011068667A1 (fr) * 2009-12-04 2011-06-09 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines et hétérocycles associés en tant qu'inhibiteurs de ck2

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845754B2 (en) 2018-10-30 2023-12-19 Kronos Bio, Inc. Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity

Also Published As

Publication number Publication date
WO2012170827A2 (fr) 2012-12-13

Similar Documents

Publication Publication Date Title
WO2012170827A3 (fr) Pyrazolopyrimidines et hétérocycles associés comme inhibiteurs de ck2
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
MX2011012369A (es) Pirazolopirimidinas y heterociclos relacionados como inhibidores de cinasa.
IN2012DN03112A (fr)
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
MX2017006366A (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa.
WO2015004533A3 (fr) Nouveaux composés bicycliques substitués utilisés comme inhibiteurs de bromodomaines
WO2015015318A3 (fr) Nouvelles quinazolones en tant qu'inhibiteurs de bromodomaine
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
BR112012013508A2 (pt) pirazolopirimidinas e heterociclos relacionados como inibidores de ck2
WO2012016133A3 (fr) Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53
MX2014005928A (es) Inhibidores ciclicos de glutaminasa.
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
PL2763982T3 (pl) Podstawione benzyloindazole do zastosowania jako inhibitory kinazy Bub1 w leczeniu chorób hiperproliferacyjnych
EA201391626A1 (ru) Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
WO2014080291A3 (fr) Dérivés biaryle servant d'inhibiteurs de bromodomaines
WO2013163190A8 (fr) Inhibiteurs d'adn pk
SG179163A1 (en) Novel tricyclic protein kinase modulators
JOP20120246B1 (ar) مركبات و تركيبات كمثبطات كيناز c-Kit
EA201890768A2 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
WO2012135113A3 (fr) Cyclopropylamines en tant qu'inhibiteurs de lsd1
MX2013012981A (es) Compuestos de indazol sustituidos como inhibidores de las cinasas de proteina.
MX339937B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
NZ700612A (en) Methods and compositions for treating ewings sarcoma family of tumors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12795997

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12795997

Country of ref document: EP

Kind code of ref document: A2